Key result
Current evidence suggests potential benefits of statins in critically ill patients with sepsis, ALI/ARDS, and aSAH, but definitive conclusions for their systematic use cannot be drawn due to study heterogeneity.
Why the study?
Does statin therapy improve clinical outcomes in critically ill patients?
Does statin therapy improve clinical outcomes in critically ill patients?
Current evidence is insufficient to recommend the systematic use of statins in critically ill patients, highlighting the need for further well-designed prospective randomized controlled trials.
Insufficient for routine statin use in critically ill patients; leaves open whether targeted RCTs can resolve heterogeneity in sepsis, ALI/ARDS, and aSAH.
The use or misuse of statins in critically ill patients recently attracted the attention of intensive care clinicians. Indeed, statins are probably the most common chronic treatment before critical illness and some recent experimental and clinical data demonstrated their beneficial effects during sepsis, acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), or after aneurismal subarachnoidal hemorrhage (aSAH). Due to the heterogeneity of current studies and the lack of well-designed prospective studies, definitive conclusions for systematic and large-scale utilization in intensive care units cannot be drawn from the published evidence. Furthermore, the extent of statins side effects in critically ill patients is still unknown. For the intensive care clinician, it is a matter of individually identifying the patient who can benefit from this therapy according to the current literature. The purpose of this review is to describe the mechanisms of actions of statins and to synthesize the clinical data that underline the relevant effects of statins in the particular setting of critical care, in an attempt to guide the clinician through his daily practice.
No takes yet. Share an insight, caveat, or question.
Loecker et al. (2012) conducted a review in Critical illness (Sepsis, ALI/ARDS, aSAH). Statins was evaluated. Current evidence suggests potential benefits of statins in critically ill patients with sepsis, ALI/ARDS, and aSAH, but definitive conclusions for their systematic use cannot be drawn due to study heterogeneity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: